Consumer medicine information

Spravato 28 mg/2 actuation Nasal spray

Esketamine

BRAND INFORMATION

Brand name

Spravato

Active ingredient

Esketamine

Schedule

S8

 

Consumer medicine information (CMI) leaflet

Please read this leaflet carefully before you start using Spravato 28 mg/2 actuation Nasal spray.

What is in this leaflet


This leaflet answers some common questions about SPRAVATO. It does not contain all the available information. It does not take the place of talking to your doctor or pharmacist.
All medicines have risks and benefits. Your doctor has weighed the risks of you taking SPRAVATO against the benefits they expect it will have for you.
If you have any concerns about taking this medicine, ask your doctor.
Keep this leaflet.
You may need to read it again.

What SPRAVATO is used for


SPRAVATO contains the active substance esketamine. This belongs to a group of medicines called antidepressants and is used to treat depression in adults.
SPRAVATO is a nasal spray used to reduce the broad range of symptoms of depression. This medicine can help improve the symptoms of your disease and reduce the chance of your symptoms coming back.
SPRAVATO is used in people who have tried other antidepressant medicines but have not benefitted from them.
Ask your doctor if you have any questions about why this medicine has been prescribed for you.
Your doctor may have prescribed it for another reason.
This medicine is available only with a doctor's prescription.

Before you use SPRAVATO

When you must not take it


Do not take SPRAVATO if you have an allergy to:
  • any medicine containing esketamine or ketamine
  • any of the ingredients listed at the end of this leaflet.

Some of the symptoms of an allergic reaction may include:
  • shortness of breath
  • wheezing or difficulty breathing
  • swelling of the face, lips, tongue or other parts of the body
  • rash, itching or hives on the skin

Do not take SPRAVATO if you have, or have had, any of the following medical conditions:
  • an aneurysm, this is a weak spot in a blood vessel wall where it widens or bulges out.
  • bleeding in the brain.

This is because SPRAVATO can cause a temporary increase in blood pressure and in both these conditions, an increase in blood pressure can cause a serious medical condition.
Do not use SPRAVATO if you are pregnant.
If you are pregnant, think you may be pregnant or are planning to have a baby, tell your doctor before using this medicine. Tell your doctor if you are trying to make your partner pregnant.
Using SPRAVATO during pregnancy has not been studied and it is not known if SPRAVATO will harm your unborn baby.
If you are able to become pregnant you must use highly effective contraception during treatment - and up to 6-weeks after the end of treatment. Talk with your doctor about methods of contraception to use.
Do not use SPRAVATO if you are breast-feeding.
The active ingredient in SPRAVATO may pass into breast milk and there is a possibility that your baby may be affected.
Your doctor will only prescribe SPRAVATO for your self-administration based on its indicated usage.
Do not take this medicine after the expiry date printed on the pack or if the packaging is torn or shows signs of tampering.
If it has expired or is damaged, your doctor or other health care professional will arrange for its disposal.
If you are not sure whether you should start taking this medicine, talk to your doctor.

Before you start to take it


Tell your doctor if you have allergies to any other medicines, foods, or preservatives.
Tell your doctor if you have or have had any of the following medical conditions:
  • heart problems which are not well controlled such as: poor blood flow in the blood vessels of the heart frequently with chest pain (such as angina), high blood pressure, a recent heart attack, heart valve disease or heart failure
  • slow or fast heartbeats causing shortness of breath, palpitations or chest discomfort, feeling light-headed or fainting
  • problems with the blood supply to your brain (such as a stroke)
  • a head injury or serious problems affecting the brain, particularly where there is increased pressure in the brain
  • problems with drug abuse – prescribed or illegal drugs - or a problem with alcohol
  • a condition called psychosis - where you believe in things that are not true (delusions) or see, feel, or hear things that are not there (hallucinations)
  • you have ever had a condition called “bipolar disorder” or symptoms of mania – where you are being very over-active or over excited
  • an overactive thyroid that is not properly treated (hyperthyroidism)
  • lung problems causing breathing difficulty (pulmonary insufficiency)
  • severe liver problems.

If any of the above apply to you (or you are not sure), talk to your doctor before using SPRAVATO. Your doctor will decide whether you should use this medicine.
Tell your doctor if you are of Japanese or Chinese ancestry.

Taking other medicines


Tell your doctor or pharmacist if you are taking any other medicines, including any that you get without a prescription from your pharmacy, supermarket or health food shop.
Some medicines and SPRAVATO may interfere with each other. These include:
  • other nasal sprays. Do not use any other nasal spray within 1 hour of using SPRAVATO.
  • Central Nervous System (CNS) depressants (for example, benzodiazepines, opioids, medicines or beverages containing alcohol)
  • Psychostimulants (for example, amphetamines, methylphenidate, modafanil, armodafinil)
  • Monoamine oxidase inhibitors (MAOIs) medicines (for example, tranylcypromine, selegiline, phenelzine)

Some medicines may be affected by SPRAVATO or may affect how well it works. You may need different amounts of your medicines, or you may need to take different medicines.
Your doctor will have more information on medicines to be careful with or avoid while taking SPRAVATO.

How to take SPRAVATO


You will use the SPRAVATO nasal spray yourself - under the supervision of your doctor or other health care professional in the doctor’s office, clinic or hospital.
SPRAVATO is used together with another antidepressant.
Follow all directions given to you by your doctor or other health care professional carefully.
Your doctor or other health care professional will show you how to use the nasal spray device and you must also read the Instructions for Use leaflet provided in the SPRAVATO pack.
If you do not understand the instructions in the Instructions for Use leaflet, ask your doctor or other health care professional for help.

How much to take


One nasal spray device delivers two sprays (one spray per nostril).
Your doctor will decide how many nasal spray devices and how often you should come to the doctor’s office or clinic for the medicine.
  • SPRAVATO is taken twice a week for the first 4 weeks.
  • For some patients, after the first 4 weeks, SPRAVATO is usually taken once a week for a further 4 weeks.
  • For some patients, after this, SPRAVATO is usually taken either once a week or once every 2 weeks.

During and after each use of this medicine, you will be checked, and your doctor or other health care professional will decide how long to monitor you.
  • This medicine may cause a temporary increase in your blood pressure after taking a dose. Your blood pressure will be checked before and after taking this medicine. Tell the medical staff right away if you get chest pain, shortness of breath, sudden severe headache, change in vision, or seizures after taking this medicine.
  • This medicine may cause sleepiness (sedation), fainting, dizziness, spinning sensation, anxiety, or feeling disconnected from yourself, your thoughts, feelings, space and time (dissociation) difficulty breathing (respiratory depression). Tell the medical staff right away if you feel like you cannot stay awake or if you feel like you are going to pass out.

How to take it


Step 1.
Your doctor or other health care professional will instruct you to blow your nose before using the first device only.
Step 2.
Your doctor or other health care professional will check the expiry date and remove the device from its blister and check that the indicator shows 2 green dots. They will then hand you the device.
DO NOT PRIME THE DEVICE
Step 3.

Hold device as shown with the thumb gently supporting the plunger. Do not press the plunger.

Recline head at about 45 degrees during administration to keep medication inside the nose.
Step 4.

Insert tip straight into the first nostril. The nose rest should touch the skin between the nostrils.

Close opposite nostril.
Breathe in through nose while pushing plunger all the way up until it stops.

Sniff gently after spraying to keep medication inside nose.

Switch hands to insert tip into the second nostril.
Repeat Step 4 to deliver second spray.
Step 5

Your doctor or other health care professional will take the used device and check that the indicator shows no green dots. If there is a green dot they will have you spray again into the second nostril.

You will then rest in a semi-reclined position for 5 minutes after each device.
DO NOT BLOW NOSE.
If any liquid runs out, dab nose with a tissue.
Repeat Steps 2 - 5 if more than one device is required.
It is important that you rest for 5 minutes after each device to allow the medication to absorb.

When to take it


You will be directed to use SPRAVATO by your doctor in the doctor’s office or clinic.
Some patients taking SPRAVATO may experience nausea or vomiting.
You should avoid eating 2 hours before and drinking liquids 30 minutes before using this medicine.
If you need steroid or decongestant medicines as a nasal spray, avoid using these medicines within 1 hour before your SPRAVATO treatment.

How long to take it


Continue using SPRAVATO for as long as your doctor tells you.

If you forget your appointment


It is important you make sure you come in for your scheduled appointments, so that this medicine is effective for you.
If you miss an appointment it is important that you contact your doctor as soon as possible to make a new appointment.

If you take too much (overdose)


This medicine will be given to you under the supervision of your doctor in the doctor’s office or clinic. Therefore, it is unlikely that you will be given too much.
However, if you experience any side effects after using SPRAVATO, tell your doctor or nurse immediately or go to Accident and Emergency at your nearest hospital.
You may need urgent medical attention.

While you are using SPRAVATO

Things you must do


Be sure to keep all your doctor's appointments so your progress can be checked.
It is important to have your follow-up doses of SPRAVATO at the appropriate times to get the best effects from your treatment.
Tell any other doctors, dentists, and pharmacists who treat you that you are taking this medicine.
If you are about to be started on any new medicine, remind your doctor and pharmacist that you are taking SPRAVATO.
If you are going to have surgery, tell the surgeon or anaesthetist that you are taking this medicine.
If you become pregnant or your partner becomes pregnant while taking this medicine, tell your doctor immediately.

Things to be careful of


Do not drive or operate machinery after taking SPRAVATO.
SPRAVATO can make you feel sleepy, dizzy, and have other side effects that can temporarily affect your ability to drive motor vehicles or use other machines and do anything where you need to be completely alert. After being treated with this medicine, do not take part in these activities until the next day following a restful sleep.
If you think your depression getting worse.
Tell your doctor or go to the nearest hospital straight away if you have suicidal thoughts or thoughts of harming yourself at any time. You may find it helpful to talk to a relative or close friend if you are depressed and ask them if they think your depression is getting worse or if they are worried about your behaviour. You might ask them to read this leaflet.
Blood Pressure
SPRAVATO can increase your blood pressure for a short time (about 1 to 2 hours) – so you will have your blood pressure measured at various times. Your blood pressure will be measured before you start using SPRAVATO and after taking it.
If your blood pressure is high before using this medicine, your doctor will decide whether to start the medicine or wait until your blood pressure is lower. If your blood pressure increases significantly after using this medicine and remains elevated for more than a few hours after dosing, your doctor may send you to another doctor for evaluation.

Side effects


Like all medicines, SPRAVATO can cause side effects although not everybody gets them. Sometimes they are serious, most of the time they are not. You may need medical attention if you get some of the side effects.
Do not be alarmed by the following lists of side effects. You may not experience any of them.
Ask your doctor to answer any questions you may have.
Tell your doctor if you notice any of the following and they worry you:

  • feeling disconnected from yourself, your thoughts, feelings and things around you
  • feeling anxious
  • feeling confused
  • difficulty in paying attention
  • change in sense of taste
  • feeling dizzy
  • feeling sleepy
  • decreased feeling or sensitivity, including around the mouth area
  • headache
  • spinning sensation (“vertigo”)
  • vomiting
  • nausea
  • increased blood pressure
  • emotional distress, crying
  • feeling extremely happy (euphoria)
  • feeling unhappy or uneasy (dysphoria)
  • problems with thinking
  • muscle tremors
  • difficulty speaking
  • fast heartbeat
  • nasal discomfort
  • throat irritation or pain
  • dry mouth
  • excessive sweating, cold sweat
  • pain when passing urine
  • frequent need to pass urine
  • feeling abnormal
  • feeling drunk
  • feeling weak with low energy (asthenia)
  • problems walking
  • fast eye movements that you cannot control
  • making movements without purpose (psychomotor hyperactivity)
  • increased saliva
  • difficulty breathing (respiratory depression)

The above list includes some side effects of your medicine.
Tell your doctor if you notice anything that is making you feel unwell.
Other side effects not listed above may also occur in some people.

After using SPRAVATO


During and after each use of SPRAVATO, you will be checked by your doctor or other health care professional who will decide how long to monitor you.
After being treated with this medicine, do not drive or use other machines that require you to be completely alert until the next day following a restful sleep.

Storage


Your doctor or healthcare professional will store your SPRAVATO for your use.
SPRAVATO should be kept in its original packaging in a cool dry place, where the temperature stays below 25°C

Disposal


Your doctor or healthcare professional will arrange to dispose of the device(s) and any medicine that is left over.
Do not take this medicine away from the clinic.
You must never be in direct possession of this medicine outside of the treatment site.

Product description

What it looks like


SPRAVATO is a nasal spray solution. It is a clear, colourless, aqueous solution provided in a pre-filled nasal spray device. Each nasal spray device is individually packaged in a sealed blister pack.
SPRAVATO is available in pack sizes containing 1, 2, or 3 single use nasal spray devices.

Ingredients


SPRAVATO contains 32.3 mg of esketamine hydrochloride (equivalent to 28 mg esketamine) as the active ingredient.
SPRAVATO also contains:
  • Citric acid monohydrate
  • Disodium edetate
  • Sodium hydroxide
  • Water for injections

SPRAVATO does not contain any preservatives, lactose, sucrose, gluten, tartrazine or any other azo dyes.

SPONSOR


JANSSEN-CILAG Pty Ltd
1-5 Khartoum Road
Macquarie Park NSW 2113 Australia
Telephone: 1800 226 334
NZ Office: Auckland New Zealand
Telephone: 0800 800 806

Registration numbers


SPRAVATO 28 mg per 2 actuations
(AUST R 311827)
This leaflet was prepared in January 2024.

BRAND INFORMATION

Brand name

Spravato

Active ingredient

Esketamine

Schedule

S8

 

Boxed Warnings

During and after Spravato administration patients must be monitored for blood pressure, sedation and dissociation until clinically stable. Spravato is to be provided by the Healthcare Professional for patients to administer under their direct supervision. Patients should be instructed not to drive or operate machinery until next day (see Section 4.2 Dose and Method of Administration). There is no safety and efficacy data for the use of Spravato in patients under 18 years old.

1 Name of Medicine

Esketamine hydrochloride.

2 Qualitative and Quantitative Composition

Spravato is a single use nasal spray device containing an intranasal solution inside the device. The solution contains esketamine hydrochloride equivalent to esketamine 28 mg/0.2 mL as the active ingredient.
Each nasal spray device delivers two actuations, one into each nostril containing a total of 32.3 mg of esketamine hydrochloride (equivalent to 28 mg of esketamine).
For the full list of excipients, see Section 6.1 List of Excipients.

3 Pharmaceutical Form

Nasal spray, solution.
Clear, colourless, aqueous solution.

4 Clinical Particulars

4.9 Overdose

No cases of overdose were reported in clinical studies with Spravato. The potential for overdose of Spravato by the patient is minimised due to the product's design and the administration taking place under the supervision of a healthcare professional (see Section 4.2 Dose and Method of Administration).
Symptoms. There is limited clinical trial experience with esketamine nasal spray doses higher than the maximum recommended dose of 84 mg. The maximum single esketamine nasal spray dose tested in healthy volunteers was 112 mg which showed no evidence of toxicity and/or adverse clinical outcomes. However, compared to the recommended dose range, the 112 mg esketamine nasal spray dose was associated with higher rates of adverse reactions including dizziness, hyperhidrosis, somnolence, hypoaesthesia, feeling abnormal, nausea and vomiting.
Management of overdose. There is no specific antidote for esketamine overdose. In the case of overdose, the possibility of multiple drug involvement should be considered. Management of Spravato overdose should consist of treating clinical symptoms and relevant monitoring. Close supervision and monitoring should continue until the patient recovers.

5 Pharmacological Properties

5.3 Preclinical Safety Data

Genotoxicity. Esketamine was not mutagenic with or without metabolic activation in the Ames test. Genotoxic effects with esketamine were seen in a screening in vitro micronucleus test in the presence of metabolic activation. However, intravenously administered esketamine was devoid of genotoxic properties in an in vivo bone marrow micronucleus test in rats and an in vivo Comet assay in rat liver cells. In simulated gastric fluid there is no evidence that N-nitroso esketamine is formed out of the fraction of the nasally administered dose of esketamine that is orally absorbed.
Carcinogenicity. The weight of evidence indicates that esketamine lacks genotoxic and carcinogenic potential in vivo.
Once daily nasal administration of esketamine did not increase the incidence of tumours in a 2-year rat carcinogenicity study at doses up to 9 mg/day. At this dose, the exposure to esketamine resembled the human exposure at the MRHD of 84 mg. Esketamine was not carcinogenic either upon once daily subcutaneous administration in a 6 month study in transgenic (Tg.rasH2) mice at doses up to 70/40 mg/kg/day. At that dose, the Cmax- and AUC-based exposure ratios for esketamine were approximately 35- and 6-fold, respectively, compared to the MRHD of 84 mg.

6 Pharmaceutical Particulars

6.7 Physicochemical Properties

Chemical structure.
https://stagingapi.mims.com/au/public/v2/images/fullchemgif/CSESKETA.gif Molecular formula: C13H16ClNO.HCl.
CAS number. 33795-24-3.

7 Medicine Schedule (Poisons Standard)

S8 Controlled Drug.

Summary Table of Changes

https://stagingapi.mims.com/au/public/v2/images/fulltablegif/SPRAVAST.gif